anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:The azulene derivative of formula I (R<1> is 1-3C alkyl; R<2> is 1-3C alkyl; R<3> is 1-6C alkyl, 6-9C aryl or 7-10C aralkyl). EXAMPLE:1-Methoxycarbonyl-3-ethyl-6-isopropylazulene. USE:Useful as an antihyperlipemic agent effective for the prevention and remedy of hyperlipemia of human and other mammals. It can be administered orally or parenterally. A cholesterol-depressing action can be maintained at a low rate of administration. PREPARATION:The compound of formula I can be produced by using hinokitiol of formula II as a starting raw material, iodinating the compound in an alkaline solution, tosylating the product in the presence of a catalyst, reducing and deiodinating the product, reacting the resultant compound of formula III with dimethyl malonate and heating the reaction product in the presence of an aldehyde and morpholine, etc.
BACKGROUND: The majority of women in low- and middle-income countries have low awareness of cervical cancer. This study sought to establish awareness of cervical cancer risk factors and preventive approaches, as well as sources of information and perceived causes of cervical cancer among secondary school girls in northern Uganda.
METHODS: This was a cross-sectional study conducted in rural northern Uganda. We collected data using an investigator administered pre-tested questionnaire. Analysis was done with STATA version 14.0. Multivariate analyses with logistic regressions models were used to determine magnitudes of association between independent and outcome variables. Odds ratios and accompanying 95% confidence intervals are reported. Statistical significance was considered if the two sided p-value <.05.
RESULTS: Most participants (97%; n = 624) had heard of cervical cancer before this study. The most common source of information about cervical cancer was friends (31.1%; n = 194). More than half of the participants (59%; n = 380) had heard about a vaccine that prevents cervical cancer, but only a third (33%; n = 124) had ever received a dose of the vaccine. The majority of participants (89%; n = 550) reported that cervical cancer could be prevented; however only half (52%; n = 290) knew that vaccination of girls aged 9-13 years could prevent cervical cancer. The majority of participants did not recognize the risk factors for cervical cancer; for example, only 15% (n = 98), 7% (n = 45), and 1.4% (n = 9) recognized early onset of sexual intercourse, infection by the human papillomavirus (HPV), and smoking respectively. On adjusting for age, students' class, and religion, students in schools with school health programs were twice (aOR = 2.24: 95%CI; 1.24-4.06) more likely to know that cervical cancer is preventable.
CONCLUSION: Secondary school girls need information on cervical cancer risk factors and approaches to prevention so that they may avoid exposures to the risk factors and promptly seek and undertake preventive approaches including HPV vaccinations.
PCT No. PCT/NL95/00149 Sec. 371 Date Jan. 22, 1997 Sec. 102(e) Date Jan. 22, 1997 PCT Filed Apr. 21, 1995 PCT Pub. No. WO95/29259 PCT Pub. Date Nov. 2, 1995This invention relates to the diagnosis of congenital defects in the anticoagulant protein C system. Methods that are disclosed are based on the detection of mutations at the cleavage sites of coagulation factors that are under control of activated protein C (APC). Diagnostic tests include analysis of the APC-cleavage sites of factor V and factor VIII, by using specific primers to amplify selectively from RNA, cDNA derived from RNA or chromosomal DNA, parts of factor V and factor VIII that contain cleavage sites for APC. Methods that monitor the presence of mutations at the cleavage sites for APC and their utility in the diagnosis of thrombo-embolic disease are disclosed. The invention further discloses methods for correcting the defects detected according to the invention, as well as novel therapeutic agents which can be used in the treatment of bleeding disorders, which agents are based on the "defective" Factor V and Factor VIII proteins leading to the thrombotic disorders described hereinabove.
You will be asked to undergo a face to face interview. During the interview, you will be asked questions about your values and feelings about your health status. You will be shown a "feeling thermometer" and asked to rate how your health condition makes you feel. You will also be asked to rate how some of the risks of treatment of cervix cancer make you feel. You will be shown a "chance board" and asked to consider some of the possible outcomes of the disease and possible risks associated with the treatment of cervix cancer. You will be asked to consider the likelihood of achieving certain outcomes and of developing certain side effects due to the disease and/or treatment. The interview will take place in a private room in the clinic and should take around 20 minutes to complete.

This is an investigational study. As many as 96 women will participate in this study. Up to 48 women who are at high risk of developing cervix cancer and up to 48 women who have been diagnosed with cervix cancer will participate. All will be enrolled at M. D. Anderson.
INTRODUCTION: In parallel with the obesity and diabetes epidemics, steatotic liver disease (SLD) has emerged as a major global public health concern. The mainstay of therapy is counseling on weight loss and increased exercise. However, such lifestyle modifications infrequently lead to success. We aimed to identify barriers to diet and lifestyle modification in patients with SLD.
METHODS: Patients with SLD completed a 14-item questionnaire that assigned barriers to healthy eating to three categories: lack of knowledge, lack of self-control, and lack of time, with a higher summary score indicating more perceived barriers. We administered assessments of health literacy and physical activity. We analyzed the data using descriptive statistics and ordinal regression analysis.
RESULTS: We included 151 participants with a median age of 64; 54% were female and 68.2% were Hispanic. Median BMI was 31.9 kg/m2. Most respondents, 68.2%, had low health literacy and were either underactive, 29.1% or sedentary, 23.2%. Lack of self-control was the strongest barrier to achieving a healthy lifestyle, followed by lack of knowledge. Lack of time was not significant barrier. Patients with the most significant barriers were more likely to have obesity, low health literacy, and be sedentary.
DISCUSSION: Lack of self-control and knowledge are the greatest barriers to adopting a healthy lifestyle in patients with SLD. Future clinical interventions should integrate education that targets various health literacy levels with behavioral approaches to improve a sense of agency.
In Buser's group early implant placement, the failing tooth was extracted atraumatically using a periotome. A collagen plug was placed to stabilize the wound clot. A healing period of 4-8 weeks was followed. Then an open flap implant surgery using a triangular flap design was cut. Implant was then placed under the crest of the palatal bone. A healing abutment was then attached. Contour augmentation was done using autogenous bone chips mixed with saline and bone conditioned medium (BCM) added to bioss bone granules to activate it.
Autophagy is a complex physiological pathway mediating homeostasis and survival of cells degrading damaged organelles and regulating their recycling. Physiologic autophagy can maintain normal lung function, decrease lung cellular senescence, and inhibit myofibroblast differentiation. It is well known that autophagy is activated in several chronic inflammatory diseases; however, its role in the pathogenesis of chronic obstructive pulmonary disease (COPD) and the expression of autophagy-related genes (ATGs) in lower airways of COPD patients is still controversial. The expression and localization of all ATG proteins that represented key components of the autophagic machinery modulating elongation, closure, and maturation of autophagosome membranes were retrospectively measured in peripheral lungs of patients with stable COPD (n = 10), control smokers with normal lung function (n = 10), and control nonsmoking subjects (n = 8) using immunohistochemical analysis. These results show an increased expression of ATG4 protein in alveolar septa and bronchiolar epithelium of stable COPD patients compared to smokers with normal lung function and non-smoker subjects. In particular, the genes in the ATG4 protein family (including ATG4A, ATG4B, ATG4C, and ATG4D) that have a key role in the modulation of the physiological autophagic machinery are the most important ATGs increased in the compartment of lower airways of stable COPD patients, suggesting that the alteration shown in COPD patients can be also correlated to impaired modulation of autophagic machinery modulating elongation, closure, and maturation of autophagosomes membranes. Statistical analysis was performed by the Kruskal-Wallis test and the Mann-Whitney U test for comparison between groups. A statistically significant increased expression of ATG4A (p = 0.0047), ATG4D (p = 0.018), and ATG5 (p = 0.019) was documented in the bronchiolar epithelium as well in alveolar lining for ATG4A (p = 0.0036), ATG4B (p = 0.0054), ATG4C (p = 0.0064), ATG4D (p = 0.0084), ATG5 (p = 0.0088), and ATG7 (p = 0.018) in patients with stable COPD compared to control groups. The ATG4 isoforms may be considered as additional potential targets for the development of new drugs in COPD.
Methods are disclosed for treating a subject with a tumor. These methods include administering to the subject a therapeutically effective amount of CD4 + ICOS + PD-1 + CXCR5 +  T cells. Methods also are disclosed for isolating a nucleic acid encoding a T cell receptor (TCR) that specifically binds a tumor cell antigen. These methods include isolating CD4 + ICOS + PD-1 + CXCR5 +  T cells from a sample from a subject with a tumor expressing the tumor cell antigen, and cloning a nucleic acid molecule encoding a TCR from the CD4 + ICOS + PD-1 + CXCR5 +  T cells. In addition, methods are disclosed for expanding CD4 + ICOS + PD-1 + CXCR5 +  T cells. In additional embodiments, methods are disclosed for determining if a subject with a tumor will respond to a checkpoint inhibitor. The methods include detecting the presence of CD4 + ICOS + PD-1 + CXCR5 +  T cells in a biological sample from a subject. Compositions of use in these methods are also disclosed.
OBJECTIVE: To explore the causal relationship between thyroid dysfunction and sepsis based on the bidirectional two-sample Mendelian randomization (MR) method.
METHODS: The genome-wide association study (GWAS) dataset were selected to screen single nucleotide polymorphisms (SNP) associated with thyroid dysfunction as instrumental variable (IV) for genetic variation, using hypothyroidism and hyperthyroidism as exposure factor and sepsis as outcome factor. Potential causal relationship between thyroid dysfunction and sepsis was analyzed using a bidirectional two-sample MR method primary analysis method of inverse-variance weighted (IVW). Potential pleiotropic analysis of SNP was performed using the MR Egger regression intercept test. Sensitivity analysis was performed using the "leave one out" test. Reverse MR method was used to prove the causal relationship.
RESULTS: The GWAS data were screened based on the three main assumptions of MR, resulting in 101 SNP strongly associated with hypothyroidism and 10 SNP strongly associated with hyperthyroidism entering the MR analysis. The results of the MR using the IVW method showed that the risk of sepsis in individuals with hypothyroidism was 2.293 times higher than those without hypothyroidism [odds ratio (OR) = 2.293, 95% confidence interval (95%CI) was 1.199-4.382, P = 0.012]. There was no significant difference in the risk of sepsis between hyperthyroid and non-hyperthyroid populations (OR = 1.049, 95%CI was 0.999-1.100, P = 0.560). MR Egger regression intercept test showed that the included SNP did not have pleiotropy, and the MR-PRESSO test did not find outliers. Sensitivity analysis suggested that the results of MR were stable. The results of the reverse MR analysis showed that the reverse causal relationship between hyperthyroidism and sepsis was not proved (OR = 0.996, 95%CI was 0.988-1.004, P = 0.338), which further confirmed the robust MR analysis result.
CONCLUSIONS: The results of the bidirectional two-sample MR analysis show that hypothyroidism can increase the risk of sepsis onset, while there is no causal relationship between hyperthyroidism and sepsis.
The invention relates to a triple inactivated vaccine for foxes and raccoon dogs and a preparation method thereof, belonging to the technical field of vaccine preparation. The vaccine consists of screened escherichia coli DC176-2 strains with the preservation numbers of CGMCC No. 25233 and Klebsiella pneumoniae FY170-1 strain, with the preservation numbers of CGMCC No. 252234 and Proteus mirabilis QY23-1 strain, and inactivated vaccine strain with the preservation number of CGMCC No. 25235 as an antigen, and can simultaneously prevent fox and raccoon dog pneumonia infected by escherichia coli, klebsiella pneumoniae, proteus mirabilis and a mixture of the three. The vaccine has the advantages of convenient preparation, low cost, no obvious side effect, better immunogenicity and safety, and can effectively provide homologous toxicity attack protection and cross protection, achieve the effect of one needle with multiple protection, simplify the immunization program of vaccination and improve the protection efficiency.
Carcinogenesis

Lifetime carcinogenicity studies were performed in CD-1 mice and Sprague-Dawley rats. There was no evidence of a carcinogenic effect in mice administered varenicline by oral gavage for 2 years at doses up to 20 mg/kg/day (47 times the maximum recommended human daily (MRHD) exposure based on AUC). Rats were administered varenicline (1, 5, and 15 mg/kg/day) by oral gavage for 2 years. In male rats (n = 65 per sex per dose group), incidences of hibernoma (tumor of the brown fat) were increased at the mid dose (1 tumor, 5 mg/kg/day, 23 times the MRHD exposure based on AUC) and maximum dose (2 tumors, 15 mg/kg/day, 67 times the MRHD exposure based on AUC). The clinical relevance of this finding to humans has not been established. There was no evidence of carcinogenicity in female rats.

Mutagenesis

Varenicline was not genotoxic, with or without metabolic activation, in the following assays: Ames bacterial mutation assay; mammalian CHO/HGPRT assay; and tests for cytogenetic aberrations in vivo in rat bone marrow and in vitro in human lymphocytes.

Impairment of Fertility

There was no evidence of impairment of fertility in either male or female Sprague-Dawley rats administered varenicline succinate up to 15 mg/kg/day (67 and 36 times, respectively, the MRHD exposure based on AUC at 1 mg twice daily). Maternal toxicity, characterized by a decrease in body weight gain, was observed at 15 mg/kg/day. However, a decrease in fertility was noted in the offspring of pregnant rats who were administered varenicline succinate at an oral dose of 15 mg/kg/day. This decrease in fertility in the offspring of treated female rats was not evident at an oral dose of 3 mg/kg/day (9 times the MRHD exposure based on AUC at 1 mg twice daily).
881,220. Drying apparatus. MONSANTO CHEMICALS (AUSTRALIA) Ltd. July 10, 1959 [July 14, 1958], No. 23787/59. Class 34(2) A method and apparatus for drying and classifying aspirin and like crystalline material comprises supplying the wet aspirin through a feeder 11, Fig. 1, into a primary fluidized bed of the material which is partially dried to a moisture content below which it is possible to maintain the bed in a fluidized state, displacing the upper surface portion of the bed through a spillway 16 down to a stand-pipe 17 into a lower secondary fluidized bed 3 having a lower fluid velocity than the primary bed whereby drying of the material is completed and the dried material is classified by stratifying into different masses of crystal-size ranges which are discharged through outlets 18, 19 at different strata levels in the bed. The beds are supplied with heated air from a blower 7 through a controlled inlet 9, which air enters through perforated screens 5, 6 supporting the beds, the cross-sectional area of the secondary bed being greater than that of the primary to lower the fluid velocity therethrough. The air is exhausted through a conduit 20 to a cyclone separator 21 wherein the crystalline fires are collected and a control 12 regulates the intake of wet material through the feeder 11 in accordance with the humidity of the exhausted air. Large agglomerates of the material which settle to the bottom of the primary bed flow across the bed to an outlet 15. In a modification the beds 1, 3, Fig. 2, are arranged side-by-side in chambers 2, 4 with the partially-dried material from the primary bed flowing over a spillway 16 which separates the beds into the secondary bed and each chamber has a controlled supply of heated air from a common blower 7 and an air outlet to a cyclone separator 21.
BACKGROUND: This review examines the impact of masculinity stigma on the diagnosis and treatment of metastatic prostate cancer, particularly in Latin America. It aims to provide insights into the influence of masculinity stigma on patient outcomes and inform strategies to address this issue.
METHODS: A comprehensive search was conducted in electronic databases (PubMed, PsycINFO, CINAHL and LILACS) using relevant keywords and controlled vocabulary related to metastatic prostate cancer, masculinity, stigma, diagnosis, and treatment up to April 2023. The search strategy was developed in consultation with a medical librarian to ensure its comprehensiveness. Thirty-three studies that investigate the role of masculinity stigma in the diagnosis and treatment of metastatic prostate cancer were included.
RESULTS: Our findings highlight the unique sociocultural influences in Latin America that shape prostate cancer stigma. It emphasizes the impact of cultural beliefs, gender norms, and social expectations on stigma. Notions of masculinity, such as strength and invulnerability, contribute to the stigmatization of prostate cancer. Machismo culture and religious/spiritual beliefs further compound the challenges and hinder open communication about the disease. Cultural taboos, limited awareness, and misconceptions perpetuate the stigma.
CONCLUSIONS: These sociocultural factors shape the experiences and challenges faced by individuals with and at risk of prostate cancer in Latin America.
The intervention is an 8-session cognitive behavior therapy (CBT) group intervention that aims to improve HIV outcomes by increasing adaptive, effective coping responses to stigma from intersectional identities related to ethnicity, immigration status, sexual minority identity, HIV status, and PrEP among Latinx sexual minority men (SMM). The intervention sessions will address topics such as: understanding and coping with intersectional stigma, multiple identities (e.g., race/ethnicity, sexual orientation), medical mistrust, social support, and structural stigma. Intervention groups will be led by a trained facilitator (with expertise in group therapy with Latinx SMM) and a trained peer co-facilitator matched in identities with participants (Latinx SMM).
FIELD: medicine. ^ SUBSTANCE: invention refers to Aloe Vera extract of family Liliaceae to be applied in pharmaceutical and food industry. Aloe Vera extract of family Liliaceae, containing mixed compound cyclolanostane and compound lophenol in certain amount where the extract produced by supercritical fluid extraction, is characterised with certain properties. There is disclosed foodstuff or beverage contains Aloe Vera extract of family Liliaceae in certain amount, method of producing Aloe Vera extract of family Liliaceae, a hyperglycemia-reducing agent containing Aloe Vera extract of family Liliaceae as an active component an extract of the Aloe belief of family Liliaceae, application of Aloe Vera extract of family Liliaceae containing mixed compound cyclolanostane and compound lophenol in certain amount to produce a hyperglycemia-reducing agent, introduction mode of Aloe Vera extract of family Liliaceae containing mixed compound cyclolanostane and compound lophenol in certain amount to reduce hyperglycemia in the medically indigent patient. ^ EFFECT: extract disclosed above develops sufficient pharmacological activity as applied in food industry and is characterised by maximally low content of anthraquinone compound. ^ 13 cl, 3 tbl, 6 ex
The efficacy of CARBAGLU in the treatment of acute and chronic hyperammonemia due to NAGS deficiency was evaluated in a retrospective case series of 23 NAGS deficiency patients treated with CARBAGLU over a median duration of 7.9 years (range 0.6 to 20.8 years). For acute treatment, patients received CARBAGLU at 100 mg/kg/day to 250 mg/kg/day orally administered in 2 to 4 divided doses. For maintenance treatment, the dosage was reduced over time based on plasma ammonia level and clinical response.

The baseline characteristics of the patient population are shown in Table 5.

The clinical and biochemical data in the 23-patient case series were retrospectively collected, unblinded and uncontrolled and preclude formal statistical testing. Short-term efficacy was evaluated using mean and median change in plasma ammonia levels from baseline to days 1 to 3. Persistence of the effect was evaluated using long-term mean and median change in plasma ammonia level. Of the 23 NAGS deficiency patients in the case series, 13 patients had documented plasma ammonia levels prior to CARBAGLU treatment and after long-term treatment with CARBAGLU and were evaluable. Table 5 summarizes the plasma ammonia levels at baseline, days 1 to 3 post-CARBAGLU treatment, and long-term CARBAGLU treatment (mean 8 years) in the 13 evaluable patients.

All 13 patients had increased plasma ammonia levels at baseline (mean 271 micromol/L; normal range: 5 to 50 micromol/L). By day 3 and with long-term treatment, normal plasma ammonia levels were attained (Table 6).

The mean plasma ammonia level at baseline and the decline that is observed after treatment with CARBAGLU in 13 evaluable patients with NAGS deficiency is illustrated in Figure 1.

Figure 1: Mean Plasma Ammonia in 13 Evaluable NAGS Deficiency Patients at Baseline and After Treatment with CARBAGLU
Volunteers will receive one administration of the high dose COVID-19 vaccine candidate on day 0 by intramuscular (i.m.) injection and one administration of the placebo on day 28 by intramuscular (i.m.) injection.
<P>PROBLEM TO BE SOLVED: To provide a hyaluronidase inhibitor having excellent hyaluronidase inhibiting effect.  <P>SOLUTION: The hyaluronidase inhibitor contains, as an effective component, a mixture prepared by combining a solvent extract from the rootstock of Bergenia ligulata (scientific name: Bergenia ligulata (Wall.) Engl.) and γ-polyglutamic acid having a molecular weight of ≤200,000. The skin care preparation including the mixture has a hyaluronidase-inhibiting action more excellent than that in the single use of γ-polyglutamic acid or the rootstock of Bergenia ligulata.  <P>COPYRIGHT: (C)2008,JPO&INPIT